Why the study?
The effects of renin–angiotensin–aldosterone system blockers on angiotensin-converting enzyme 2 levels and activity in humans are uncertain.
Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
Effects of RAAS inhibitors on ACE2 remain uncertain in COVID-19; leaves open optimal management and need for targeted trials.
RAAS Inhibitors in Patients with Covid-19 The effects of renin–angiotensin–aldosterone system blockers on angiotensin-converting enzyme 2 levels and activity in humans are uncertain.
No takes yet. Share an insight, caveat, or question.
Vaduganathan et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: